Breaking News

Tweet TWEET

Evotec Enters Integrated Alliance With AstraZeneca in Kidney Disease

Evotec Enters Integrated Alliance With AstraZeneca in Kidney Disease

HAMBURG, Germany, Oct. 21, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT)
(TecDAX) (ISIN: DE0005664809) today announced that it has signed an agreement
with AstraZeneca in the field of kidney diseases. Initial focus of the
alliance will be exploring compounds and targets with novel mechanisms that
have disease-modifying potential for the treatment of chronic kidney disease.

Under the terms of this licence and collaboration agreement, AstraZeneca will
receive access to a selected series of molecules identified in a screening
effort, which is part of Evotec's systematic kidney disease initiative. This
particular programme has been designed to explore a key mechanism in the field
of chronic kidney disease. AstraZeneca will provide industrial scope and scale
as well as pharmaceutical development expertise and marketing capabilities.

The agreement between Evotec and AstraZeneca triggers an undisclosed upfront
payment as well as pre-clinical, clinical and regulatory milestones. Evotec is
also eligible for additional milestone and royalty payments related to
commercialisation. Evotec will receive research funding for work that will be
conducted in collaboration with AstraZeneca. Specific financial details were
not disclosed.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "Exploring
novel mechanisms and novel targets in the field of kidney disease is a logical
next step for Evotec. We are very excited about AstraZeneca joining one of our
programmes. AstraZeneca is a great partner sharing not only our vision but
making valuable contributions beyond in an integrated discovery and
development process."

Dr Marcus Schindler, Head of Cardiovascular and Metabolic Diseases iMed,
AstraZeneca, added: "Cardiovascular and metabolic diseases (CVMD) represents
one of the three core areas for AstraZeneca. Within CVMD, we are committing
significant efforts on research and development of potential new treatments
for diabetic nephropathy, end-stage as well as chronic kidney disease. Our
goal is to identify and develop effective therapies to halt or slow down the
decline of renal function for patients suffering from kidney diseases. This
new collaboration complements our research efforts in the renal disease space.
Evotec has built a leading drug discovery platform in the field of kidney
diseases and is well-positioned to work with us to generate highly innovative
drug candidates so that we can accelerate the delivery of new medicines to
patients."

ABOUT EVOTECAG

Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing the
highest quality stand-alone and integrated drug discovery solutions, covering
all activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and expertise
in key therapeutic areas including neuroscience, pain, metabolic diseases as
well as oncology and inflammation. Evotec has long-term discovery alliances
with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen
Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition,
the Company has existing development partnerships and product candidates both
in clinical and pre-clinical development. These include partnerships with
Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes,
with Janssen Pharmaceuticals in the field of depression and with Roche in the
field of Alzheimer's disease. For additional information please go to
www.evotec.com.

ABOUT ASTRAZENECA

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: astrazeneca.com.

In cardiovascular and metabolic diseases AstraZeneca focuses the small
molecule research on three strategic areas: Cardiac Regeneration, Islet Health
(diabetes) and Diabetic Nephropathy.

FORWARD LOOKING STATEMENTS — Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety
of risks and uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in events,
conditions or circumstances on which any such statement is based.

CONTACT: Gabriele Hansen
         Head of Corporate Communications
         +49.(0)40.560 81-255
         +49.(0)40.560 81-222 Fax
         gabriele.hansen@evotec.com
        
         Evotec AG
         Manfred Eigen Campus
         Essener Bogen 7
         22419 Hamburg (Germany)